http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Xeris (XERS) Ships One Millionth Gvoke Unit
-
Xeris Ships One Millionth Gvoke® Unit
-
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
-
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
-
Xeris Biopharma Reports First Quarter 2023 Financial Results
-
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
-
Xeris Pharmaceuticals (XERS) Issued US Patent Covering XeriSol Formulations
-
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
-
Xeris Pharmaceuticals (XERS) Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect
-
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
-
Xeris Pharmaceuticals (XERS) Appoints Ricki Fairley to its Board
-
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
-
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
-
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
-
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
-
Xeris Pharmaceuticals Inc. (XERS) Granted FDA Orphan-drug Exclusivity for Recorlev
-
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
-
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Xeris Pharmaceuticals (XERS) Revises 2022 Outlook Upwards
-
Xeris Biopharma Updates Its Outlook For 2022
-
Xeris Pharmaceuticals (XERS) Announces Plans for Phase II Dose-Finding Study for Its Investigational Subcutaneous Levothyroxine as Replacement Therapy for Hypothyroidism
-
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
-
Xeris (XERS) Enters Research Collaboration and Option Agreement With Horizon (HZNP) for XeriJect Formulation of Teprotumumab
-
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
-
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
-
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
-
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
-
Xeris Pharmaceuticals (XERS) Reports Positive Phase 1 Clinical Data of Levothyroxine
-
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
-
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
-
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
-
Xeris Pharmaceuticals' (XERS) Partner Tetris Pharma Acquires by Arecor Therapeutics
-
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
-
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
-
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
-
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
-
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
-
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
-
Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital
-
Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
-
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
Xeris Pharmaceuticals Inc. (XERS) Announces Recorlev Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
-
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
-
Xeris Pharmaceuticals Inc. (XERS) Reaffirms 2021 Guidance and Provides Business Update
-
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
-
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome
-
Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
-
Xeris Pharmaceuticals Inc. (XERS) Enters Into Agreement for $30 Million Private Placement
-
Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
